Frederic Debordeaux

Dr. Frederic Debordeaux

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
DKDavid Kryza
David Kryza
FDFrederic Debordeaux
Frederic Debordeaux
LALaurent Azéma
Laurent Azéma
AHAref Hassan
Aref Hassan
OPOlivier Paurelle
Olivier Paurelle
Jean-Jacques  ToulméJean-Jacques Toulmé
Jean-Jacques Toulmé
The human Matrix MetalloProtease-9 (hMMP-9) is overexpressed in tumors where it promotes the release of cancer cells thus contributing to tumor metastasis. We raised aptamers against hMMP-9, which constitutes a validated marker of malignant tumors, in order to design probes for imaging tumors in human beings. A chemically modified RNA aptamer (F3B), fully resistant to nucleases was previously described. This compound was subsequently used for the preparation of F3B-Cy5, F3B-S-acetylmercaptoacetyltriglycine (MAG) and F3B-DOTA. The binding properties of these derivatives were determined by surface plasmon resonance and electrophoretic mobility shift assay. Optical fluorescence imaging confirmed the binding to hMMP-9 in A375 melanoma bearing mice. Quantitative biodistribution studies were performed at 30 min, 1h and 2 h post injection of 99mTc-MAG-aptamer and 111In-DOTA-F3B. 99mTc radiolabeled aptamer specifically detected hMMP-9 in A375 melanoma tumors but accumulation in digestive tract was very high. Following i.v. injection of 111In-DOTA-F3B, high level of radioactivity was observed in kidneys and bladder but digestive tract uptake was very limited. Tumor uptake was significantly (student t test, p<0.05) higher for 111In-DOTA-F3B with 2.0%ID/g than for the 111In-DOTA-control oligonucleotide (0.7%ID/g) with tumor to muscle ratio of 4.0. Such difference in tumor accumulation has been confirmed by ex vivo scintigraphic images performed at 1h post injection and by autoradiography, which revealed the overexpression of hMMP-9 in sections of human melanomas. These results demonstrate that F3B aptamer is of interest for detecting hMMP-9 in melanoma tumor.

1 July 2018 in Nuclear Medicine and Biology
Verified
Journal Article
Closed access
FDFrederic Debordeaux
Frederic Debordeaux
LCLucie Chansel-Debordeaux
Lucie Chansel-Debordeaux
JPJean-Baptiste Pinaquy
Jean-Baptiste Pinaquy
PFPhilippe Fernandez
Philippe Fernandez
JSJurgen Schulz
Jurgen Schulz

21 October 2022 in Diagnostic and Interventional Imaging
Verified
Journal Article
Closed access
GPGoudarz T. Passand
Goudarz T. Passand
AMArthur Marichez
Arthur Marichez
FDFrederic Debordeaux
Frederic Debordeaux
JPJean-Baptiste Pinaquy
Jean-Baptiste Pinaquy
LCLaurence Chiche
Laurence Chiche

1 December 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
SBSalma Binzaqr
Salma Binzaqr
FDFrederic Debordeaux
Frederic Debordeaux
JBJean-frederic Blanc
Jean-frederic Blanc
PPPanteleimon Papadopoulos
Panteleimon Papadopoulos
Elif HindiéElif Hindié
Elif Hindié
JPJean-Baptiste Pinaquy
Jean-Baptiste Pinaquy
Hepatocellular carcinoma (HCC) is one of the most common neoplasms worldwide and the third most common cause of cancer-related death. Several liver-targeted intra-arterial therapies are available for unresectable HCC, including selective internal radiation therapy (SIRT) and trans-arterial chemoembolization (TACE). Those two are the most used treatment modalities in localized non-operable HCC. TACE is the treatment option for patients with stage B, according to the BCLC staging system. In contrast, SIRT does not have an official role in the treatment algorithm, but recent studies showed promising outcomes in patients treated with SIRT. Although TACE is globally a safe procedure, it might provoke several vascular complications such as spasms, inflammatory constriction, and, in severe cases, occlusion, dissection, or collateralization. Hence, it is acclaimed that those complications could restrain the targeted response of the radio-embolization when we use it as second-line therapy post TACE. In this study, we will assess the efficacity of SIRT using Yttrium 90 Microspheres post incomplete or failure response to TACE. In our retrospective study, we had 23 patients who met the inclusion criteria. Furthermore, those patients have been followed radiologically and biologically. Then, we evaluated the therapeutic effect according to the mRECIST criteria, in addition to the personalized dose analysis. We found 8 patients were treated with TheraSphere®, with a median tumor absorbed dose of 445 Gy, while 15 received SIR-Spheres® treatment with a mean tumor dose of 268 Gy. After radiological analysis, 56.5% of the patients had a complete response, and 17.3% showed partial response, whereas 13% had stable disease and 13% had progressive disease. For patients treated with SIRT after an incomplete response or failure to TACE, we found an objective response rate of 73.8%. Despite the known vascular complications of TACE, SIRT can give a favorable response.

7 July 2015 in RSC Advances
Verified
Journal Article
Closed access
PDF file
FDFrederic Debordeaux
Frederic Debordeaux
JSJürgen Schulz
Jürgen Schulz
CSCatherine Savona-Baron
Catherine Savona-Baron
PHPuja Panwar Hazari
Puja Panwar Hazari
CLCyril Lervat
Cyril Lervat
PFPhilippe Fernandez
Philippe Fernandez
A new99mTc-labeled bivalent DTPA-bis-c(RGDfK) conjugate has been developed and successfully synthesized. Promising results have been obtained for its preclinical evaluation on human glioma and melanoma tumor expressing αvβ3targets.

3 March 2023 in Nuclear Medicine Communications
Verified
Journal Article
Closed access
JPJean-Baptiste Pinaquy
Jean-Baptiste Pinaquy
BLBruno Lapuyade
Bruno Lapuyade
JBJean-Frederic Blanc
Jean-Frederic Blanc
EHElif Hindié
Elif Hindié
PPPanteleimon Papadopoulos
Panteleimon Papadopoulos
FDFrederic Debordeaux
Frederic Debordeaux
Introduction: The calculation of resin yttrium-90 (90Y-) microspheres activity for selective internal radiotherapy (SIRT) needs to be investigated. Methods and materials: Analyses using Simplicit90Y (Boston Scientific, Natick, Massachusetts, USA) dosimetry software were performed to determine the concordance between the absorbed doses to the tumor (DT1 and DT2) and healthy liver (DN1 and DN2) during the pre-treatment and the post-treatment phases. An optimized calculation of the activity of 90Y-microspheres performed using dosimetry software was applied retrospectively to assess the impact of this calculation method on the treatment. Results: DT1 ranged from 38.8 to 372 Gy, with a mean value of 128.9 ± 73.6 Gy and median of 121.2 Gy [interquartile range (IQR): 81.7–158.8 Gy]. The median DN1 and DN2 was 10.5 Gy (IQR: 5.8–17.6). A significant correlation was between DT1 and DT2 (r = 0.88, P < 0.001) and DN1 and DN2 (r = 0.96, P < 0.001). The optimized activities were calculated; the target dose to the tumor compartment was 120 Gy. No activity reduction was applied in accordance with the tolerance of the healthy liver. Optimization of the microspheres dosages would have resulted in a significant increase in activity for nine treatments (0.21–2.54 GBq) and a reduction for seven others (0.25–0.76 GBq). Conclusions: The development of customized dosimetry software adapted to clinical practice makes it possible to use dosimetry to optimize the dosage for each patient.